Litcius/Paper detail

Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial

Wanpu Yan, Wen‐Zhao Zhong, Yan‐Hui Liu, Qixun Chen, Wenqun Xing, Qin Zhang, Lunxu Liu, Di Ge, Ke‐Neng Chen, Fan Yang, Xiang Lin, Li Song, Wei Shi, Yi‐Long Wu

2022Journal of Thoracic Oncology33 citationsDOI

Topics & Concepts

MedicineCarboplatinPerioperativeAdverse effectClinical endpointStage (stratigraphy)Confidence intervalInternal medicineSurgeryPaclitaxelChemotherapyResponse Evaluation Criteria in Solid TumorsNeoadjuvant therapyPhases of clinical researchGastroenterologyRandomized controlled trialCancerCisplatinBreast cancerPaleontologyBiologyColorectal and Anal CarcinomasPancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers
Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial | Litcius